Compare AIRS & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRS | DTIL |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.4M | 197.9M |
| IPO Year | 2021 | 2019 |
| Metric | AIRS | DTIL |
|---|---|---|
| Price | $1.23 | $6.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.50 | ★ $29.40 |
| AVG Volume (30 Days) | ★ 826.2K | 230.5K |
| Earning Date | 11-06-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $151,818,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.16 | $3.53 |
| 52 Week High | $12.00 | $9.62 |
| Indicator | AIRS | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 24.50 | 53.58 |
| Support Level | N/A | $6.62 |
| Resistance Level | $3.31 | $6.92 |
| Average True Range (ATR) | 0.13 | 0.38 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 8.57 | 81.74 |
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).